Related Experiment Video

Updated: Jul 15, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Development trends for monoclonal antibody cancer therapeutics

Janice M Reichert1, Viia E Valge-Archer

  • 1Tufts Center for the Study of Drug Development, Tufts University, 192 South Street, Suite 550, Boston, Massachusetts 02111, USA. janice.reichert@tufts.edu

Nature Reviews. Drug Discovery
|April 14, 2007
PubMed

Insights

Monoclonal antibodies are a vital cancer treatment. This review examines their clinical development and regulatory approval trends since 1980 to guide future cancer therapeutic research.

Area of Science:

  • Oncology
  • Immunotherapy
  • Drug Development

Background:

  • Monoclonal antibodies (mAbs) are a significant therapeutic class for various diseases.
  • Cancer is a primary focus for mAb development due to their tumor-targeting capabilities.

Purpose of the Study:

  • To overview trends in clinical development of monoclonal antibodies for cancer.
  • To analyze regulatory approval patterns for cancer-targeting mAbs since 1980.
  • To inform future research and development strategies for therapeutic mAbs.

Main Methods:

  • Literature review of clinical trials and regulatory databases.
  • Analysis of trends in monoclonal antibody development for cancer from 1980 onwards.

Main Results:

  • Significant growth in clinical development and regulatory approvals of cancer mAbs.
  • Identification of key trends shaping the landscape of mAb therapeutics in oncology.

Conclusions:

  • Monoclonal antibodies have a well-established role in cancer therapy.
  • Understanding historical development trends is crucial for advancing future cancer mAb research and clinical application.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...